Application of Machine Learning Methods for the Development of Antidiabetic
Drugs

Juanjuan       Zhao; Pengcheng       Xu; Xiujuan       Liu; Xiaobo       Ji; Minjie       Li; Dev       Sooranna; Xiaosheng       Qu; Wencong       Lu; Bing       Niu
Abstract

Diabetes is a chronic non-communicable disease caused by several different routes, which has attracted increasing attention. In order to speed up the development of new selective drugs, machine learning (ML) technology has been applied in the process of diabetes drug development and opens up a new blueprint for drug design. This review provides a comprehensive portrayal of the application of ML in antidiabetic drug use.
Keywords: Antidiabetic drugs, mechanism of action, machine learning, hypoglycemic action, inhibitory activity, DPP-IV inhibitors.
[1] 
Javeed N, Matveyenko AV. Circadian etiology of type 2 diabetes mellitus. Physiology (Bethesda)  2018; 33(2): 138-50.
[http://dx.doi.org/10.1152/physiol.00003.2018] [PMID:  29412061] 
[2] 
Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review. Diabet Med  2007; 24(4): 333-43.
[http://dx.doi.org/10.1111/j.1464-5491.2007.02106.x] [PMID:  17367307] 
[3] 
Kores K, Konc J, Bren U. Mechanistic insights into side effects of troglitazone and rosiglitazone using a novel inverse molecular docking protocol. Pharmaceutics  2021; 13(3): 13.
[http://dx.doi.org/10.3390/pharmaceutics13030315] [PMID:  33670968] 
[4] 
Connelly PJ, Lonergan M, Soto-Pedre E, Donnelly L, Zhou K, Pearson ER. Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study. Diabetes Obes Metab  2017; 19(11): 1579-86.
[http://dx.doi.org/10.1111/dom.12978] [PMID:  28432751] 
[5] 
Seo YG. Side effects associated with liraglutide treatment for obesity as well as diabetes. J Obes Metab Syndr  2021; 30(1): 12-9.
[http://dx.doi.org/10.7570/jomes20059] [PMID:  33071241] 
[6] 
Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov  2019; 18(6): 463-77.
[http://dx.doi.org/10.1038/s41573-019-0024-5] [PMID:  30976107] 
[7] 
Staels B. PPAR agonists and the metabolic syndrome. Therapie  2007; 62(4): 319-26.
[http://dx.doi.org/10.2515/therapie:2007051] [PMID:  17983557] 
[8] 
Augustyns K, Van der Veken P, Senten K, Haemers A. The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr Med Chem  2005; 12(8): 971-98.
[http://dx.doi.org/10.2174/0929867053507298] [PMID:  15853709] 
[9] 
Brunton SA, Wysham CH. GLP-1 receptor agonists in the treatment
	of type 2 diabetes: Role and clinical experience to date Postgrad
	Med 2020; 132(sup2): 3-14 
[http://dx.doi.org/10.1080/00325481.2020.1798099] [PMID: 32815454] 
[10] 
Qian S, Zhang M, He Y, Wang W, Liu S. Recent advances in the development of protein tyrosine phosphatase 1B inhibitors for Type 2 diabetes. Future Med Chem  2016; 8(11): 1239-58.
[http://dx.doi.org/10.4155/fmc-2016-0064] [PMID:  27357615] 
[11] 
Wang H, Iynedjian PB. Modulation of glucose responsiveness of insulinoma beta-cells by graded overexpression of glucokinase. Proc Natl Acad Sci USA  1997; 94(9): 4372-7.
[http://dx.doi.org/10.1073/pnas.94.9.4372] [PMID:  9113996] 
[12] 
Ferre T, Riu E, Bosch F, Valera A. Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver. FASEB J  1996; 10(10): 1213-8.
[http://dx.doi.org/10.1096/fasebj.10.10.8751724] [PMID:  8751724] 
[13] 
Panahi F, Yousefi R, Mehraban MH, Khalafi-Nezhad A. Synthesis of new pyrimidine-fused derivatives as potent and selective antidiabetic α-glucosidase inhibitors. Carbohydr Res  2013; 380: 81-91.
[http://dx.doi.org/10.1016/j.carres.2013.07.008] [PMID:  23978663] 
[14] 
Poudel RR. Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition. Indian J Endocrinol Metab  2013; 17(4): 588-93.
[http://dx.doi.org/10.4103/2230-8210.113725] [PMID:  23961473] 
[15] 
Park TC, Kim TY, Yeo YK. Prediction of the melt flow index using partial least squares and support vector regression in high-density polyethylene (HDPE) process. Korean J Chem Eng  2010; 27: 1662-8.
[http://dx.doi.org/10.1007/s11814-010-0280-x] 
[16] 
Borucka A. Logistic regression in modeling and assessment of transport services. Open Eng  2020; 10: 26-34.
[http://dx.doi.org/10.1515/eng-2020-0029] 
[17] 
Garcia-Carretero R, Vigil-Medina L, Mora-Jimenez I, Soguero-Ruiz C, Barquero-Perez O, Ramos-Lopez J. Use of a K-nearest neighbors model to predict the development of type 2 diabetes within 2 years in an obese, hypertensive population. Med Biol Eng Comput  2020; 58(5): 991-1002.
[http://dx.doi.org/10.1007/s11517-020-02132-w] [PMID:  32100174] 
[18] 
Pal M, Mather PM. An assessment of the effectiveness of decision tree methods for land cover classification. Remote Sens Environ  2003; 86: 554-65.
[http://dx.doi.org/10.1016/S0034-4257(03)00132-9] 
[19] 
Ma B, Wang X, Li Q, et al. Adaptive error prediction method based on multiple linear regression for reversible data hiding. J Real-Time Image Process  2019; 16: 821-34.
[http://dx.doi.org/10.1007/s11554-019-00891-w] 
[20] 
Cherkassky V. The nature of statistical learning theory. IEEE Trans Neural Netw  1997; 8(6): 1564.
[http://dx.doi.org/10.1109/TNN.1997.641482] [PMID:  18255760] 
[21] 
Tharwat A. Parameter investigation of support vector machine classifier with kernel functions. Knowl Inf Syst  2019; 61: 1269-302.
[http://dx.doi.org/10.1007/s10115-019-01335-4] 
[22] 
Kosiński RA, Kozłowski C. Artificial neural networks-modern systems for safety control. Int J Occup Saf Ergon  1998; 4(3): 317-32.
[http://dx.doi.org/10.1080/10803548.1998.11076397] [PMID:  10602625] 
[23] 
Watson P. Naïve Bayes classification using 2D pharmacophore feature triplet vectors. J Chem Inf Model  2008; 48(1): 166-78.
[http://dx.doi.org/10.1021/ci7003253] [PMID:  18183968] 
[24] 
Chen L, Li Y, Zhao Q, Peng H, Hou T. ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques. Mol Pharm  2011; 8(3): 889-900.
[http://dx.doi.org/10.1021/mp100465q] [PMID:  21413792] 
[25] 
Ling Y, Yue Q, Chai C, Shan Q, Hei D, Jia W. Nuclear accident source term estimation using kernel principal component analysis, particle swarm optimization, and backpropagation neural networks. Ann Nucl Energy  2020; 136(2)107031
[http://dx.doi.org/10.1016/j.anucene.2019.107031] 
[26] 
Harmon GS, Lam MT, Glass CK. PPARs and lipid ligands in inflammation and metabolism. Chem Rev  2011; 111(10): 6321-40.
[http://dx.doi.org/10.1021/cr2001355] [PMID:  21988241] 
[27] 
Jung Y, Cao Y, Paudel S, et al. A Novel Partial PPARα/γ dual agonist SN159 improves insulin sensitivity. Bull Korean Chem Soc  2016; 37: 226-33.
[http://dx.doi.org/10.1002/bkcs.10662] 
[28] 
Michalik L, Auwerx J, Berger JP, et al. International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev  2006; 58(4): 726-41.
[http://dx.doi.org/10.1124/pr.58.4.5] [PMID:  17132851] 
[29] 
Qian X, Wang H, Yang G, et al. Pioglitazone improved insulin sensitivity and first phase insulin secretion among obese and lean people with diabetes: A multicenter clamp study. Diabetes Ther  2018; 9(2): 815-26.
[http://dx.doi.org/10.1007/s13300-018-0401-9] [PMID:  29536426] 
[30] 
Verma N, Chouhan U. Chemometric modelling of PPAR-alpha and PPAR-gamma dual agonists for the treatment of type-2 diabetes. Curr Sci  2016; 111: 356-67.
[http://dx.doi.org/10.18520/cs/v111/i2/356-367] 
[31] 
Verma N, Chouhan U. In-silico analysis of phenyl propanoic acid derivatives to design potent peroxisome proliferator-activated receptor (PPAR) dual agonists for type 2 diabetes mellitus therapy. Orient J Chem  2018; 34: 1400-10.
[http://dx.doi.org/10.13005/ojc/340329] 
[32] 
Verma N, Chouhan U. Pharmacoinformatic Studies on 4-Thiazolyl-phenoxy tail containing indanyl acetic acid derivatives as PPAR-Pan agonists as potent anti-diabetic agent. Indian J Pharm Edu Res  2019; 53: s288-98.
[http://dx.doi.org/10.5530/ijper.53.3s.99] 
[33] 
Hui H, Zhao X, Perfetti R. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes Metab Res Rev  2005; 21(4): 313-31.
[http://dx.doi.org/10.1002/dmrr.553] [PMID:  15852457] 
[34] 
Ahrén B, Holst JJ, Mari A. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes Care  2003; 26(10): 2860-4.
[http://dx.doi.org/10.2337/diacare.26.10.2860] [PMID:  14514592] 
[35] 
Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol  2003; 82(2): 53-73.
[http://dx.doi.org/10.1078/0171-9335-00302] [PMID:  12647932] 
[36] 
Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care  2014; 37(8): 2149-58.
[http://dx.doi.org/10.2337/dc13-2761] [PMID:  24742660] 
[37] 
Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet  2009; 374(9683): 39-47.
[http://dx.doi.org/10.1016/S0140-6736(09)60659-0] [PMID:  19515413] 
[38] 
Murphy CE. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus. Ann Pharmacother  2012; 46(6): 812-21.
[http://dx.doi.org/10.1345/aph.1Q722] [PMID:  22669803] 
[39] 
Lee J, Cho YK, Kim HS, Jung CH, Park JY, Lee WJ. Dulaglutide as an add-on to insulin in type 2 diabetes; clinical efficacy and parameters affecting the response in real-world practice. Diabetes Metab Syndr Obes  2019; 12: 2745-53.
[http://dx.doi.org/10.2147/DMSO.S231272] [PMID:  31920354] 
[40] 
Toyoda M, Yokoyama H, Abe K, Nakamura S, Suzuki D. Predictors of response to liraglutide in Japanese type 2 diabetes. Diabetes Res Clin Pract  2014; 106(3): 451-7.
[http://dx.doi.org/10.1016/j.diabres.2014.09.052] [PMID:  25458335] 
[41] 
Wang T, Zhang F, Wang X, et al. Predictive factors associated with glycaemic response to exenatide in Chinese patients with type 2 diabetes mellitus. J Clin Pharm Ther  2020; 45(5): 1050-7.
[http://dx.doi.org/10.1111/jcpt.13134] [PMID:  32176827] 
[42] 
Davies M, Heller S, Sreenan S, et al. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care  2013; 36(5): 1368-76.
[http://dx.doi.org/10.2337/dc12-1333] [PMID:  23275363] 
[43] 
Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol  2003; 10(1): 19-25.
[http://dx.doi.org/10.1038/nsb882] [PMID:  12483204] 
[44] 
Nabeno M, Akahoshi F, Kishida H, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun  2013; 434(2): 191-6.
[http://dx.doi.org/10.1016/j.bbrc.2013.03.010] [PMID:  23501107] 
[45] 
Hunziker D, Hennig M, Peters JU. Inhibitors of dipeptidyl peptidase IV-recent advances and structural views. Curr Top Med Chem  2005; 5(16): 1623-37.
[http://dx.doi.org/10.2174/156802605775009685] [PMID:  16375746] 
[46] 
Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab  2011; 13(9): 775-83.
[http://dx.doi.org/10.1111/j.1463-1326.2011.01414.x] [PMID:  21507182] 
[47] 
Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem  2005; 48(1): 141-51.
[http://dx.doi.org/10.1021/jm0493156] [PMID:  15634008] 
[48] 
Yoshida T, Akahoshi F, Sakashita H, et al. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem  2012; 20(19): 5705-19.
[http://dx.doi.org/10.1016/j.bmc.2012.08.012] [PMID:  22959556] 
[49] 
Yoshida N, Babazono T, Hanai K, Uchigata Y. Switching from subcutaneous insulin injection to oral vildagliptin administration in hemodialysis patients with type 2 diabetes: A pilot study. Int Urol Nephrol  2016; 48(8): 1349-55.
[http://dx.doi.org/10.1007/s11255-016-1305-0] [PMID:  27193434] 
[50] 
Kim HM, Lim JS, Lee BW, Kang ES, Lee HC, Cha BS. Optimal candidates for the switch from glimepiride to sitagliptin to reduce hypoglycemia in patients with type 2 diabetes mellitus. Endocrinol Metab (Seoul)  2015; 30(1): 84-91.
[http://dx.doi.org/10.3803/EnM.2015.30.1.84] [PMID:  25325279] 
[51] 
Kubota A, Maeda H, Kanamori A, et al. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J Diabetes Investig  2012; 3(6): 503-9.
[http://dx.doi.org/10.1111/j.2040-1124.2012.00221.x] [PMID:  24843615] 
[52] 
Suh S, Song SO, Kim JH, Cho H, Lee WJ, Lee BW. Effectiveness of vildagliptin in clinical practice: Pooled analysis of three Korean observational studies (the victory study). J Diabetes Res  2017; 20175282343
[http://dx.doi.org/10.1155/2017/5282343] [PMID:  29057274] 
[53] 
Campbell SA, Light PE, Simpson SH. Costarting sitagliptin with metformin is associated with a lower likelihood of disease progression in newly treated people with type 2 diabetes: a cohort study. Diabet Med  2020; 37(10): 1715-22.
[PMID: 31618475] 
[54] 
Kadowaki T, Sasaki K, Ishii M, Matsukawa M, Ushirogawa Y. Efficacy and safety of teneligliptin 40 mg in type 2 diabetes: a pooled analysis of two phase III clinical studies. Diabetes Ther  2018; 9(2): 623-36.
[http://dx.doi.org/10.1007/s13300-018-0372-x] [PMID:  29435909] 
[55] 
Saqib U, Siddiqi MI. 3D-QSAR studies on triazolopiperazine amide inhibitors of dipeptidyl peptidase-IV as anti-diabetic agents. SAR QSAR Environ Res  2009; 20(5-6): 519-35.
[http://dx.doi.org/10.1080/10629360903278677] [PMID:  19916112] 
[56] 
Jiang YK. Molecular docking and 3D-QSAR studies on beta-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors. J Mol Model  2010; 16(7): 1239-49.
[http://dx.doi.org/10.1007/s00894-009-0637-4] [PMID:  20069322] 
[57] 
Zeng J, Liu G, Tang Y, Jiang H. 3D-QSAR studies on fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors by CoMFA and CoMSIA. J Mol Model  2007; 13(9): 993-1000.
[http://dx.doi.org/10.1007/s00894-007-0221-8] [PMID:  17618469] 
[58] 
Paliwal S, Seth D, Yadav D, Yadav R, Paliwal S. Development of a robust QSAR model to predict the affinity of pyrrolidine analogs for dipeptidyl peptidase IV (DPP- IV). J Enzyme Inhib Med Chem  2011; 26(1): 129-40.
[http://dx.doi.org/10.3109/14756361003777057] [PMID:  21299434] 
[59] 
Yang X, Li M, Su Q, Wu M, Gu T, Lu W. QSAR studies on pyrrolidine amides derivatives as DPP-IV inhibitors for type 2 diabetes. Med Chem Res  2013; 22: 5274-83.
[http://dx.doi.org/10.1007/s00044-013-0527-2] 
[60] 
Gu TH, Yang XY, Li MJ, et al. Predicting the DPP-IV inhibitory activity pIC(50) based on their physicochemical properties. BioMed Res Int  2013; 2013: 7.
[http://dx.doi.org/10.1155/2013/798743] 
[61] 
Patil RB, Barbosa EG, Sangshetti JN, Zambre VP, Sawant SD. Structural insights of dipeptidyl peptidase-IV inhibitors through molecular dynamics-guided receptor-dependent 4D-QSAR studies. Mol Divers  2018; 22(3): 575-83.
[http://dx.doi.org/10.1007/s11030-018-9815-6] [PMID:  29536226] 
[62] 
Zhang Z, Wallace MB, Feng J, et al. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. J Med Chem  2011; 54(2): 510-24.
[http://dx.doi.org/10.1021/jm101016w] [PMID:  21186796] 
[63] 
Liu Y, Hu Y, Liu T. Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects. Curr Med Chem  2012; 19(23): 3982-99.
[http://dx.doi.org/10.2174/092986712802002491] [PMID:  22709010] 
[64] 
Aoki C, Suzuki K, Kuroda H, et al. Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index. Nagoya J Med Sci  2017; 79(1): 9-16.
[PMID: 28303056] 
[65] 
Amini Z, Fatemi MH, Gharaghani S. Hybrid docking-QSAR studies of DPP-IV inhibition activities of a series of aminomethyl-piperidones. Comput Biol Chem  2016; 64: 335-45.
[http://dx.doi.org/10.1016/j.compbiolchem.2016.08.003] [PMID:  27570070] 
[66] 
Piyush G, Kumar JS. Ligand Based in-silico Study on pyridopyrimidinedione derivatives as dipeptidyl peptidase-IV inhibitors. Indian J Pharm Edu Res  2017; 51: 664-71.
[http://dx.doi.org/10.5530/ijper.51.4.98] 
[67] 
Al-Masri IM, Mohammad MK, Taha MO. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening. ChemMedChem  2008; 3(11): 1763-79.
[http://dx.doi.org/10.1002/cmdc.200800213] [PMID:  18989859] 
[68] 
Cai J, Li C, Liu Z, et al. Predicting DPP-IV inhibitors with machine learning approaches. J Comput Aided Mol Des  2017; 31(4): 393-402.
[http://dx.doi.org/10.1007/s10822-017-0009-6] [PMID:  28155089] 
[69] 
Yan F, Liu X, Zhang S, Su J, Zhang Q, Chen J. Computational revelation of binding mechanisms of inhibitors to endocellular protein tyrosine phosphatase 1B using molecular dynamics simulations. J Biomol Struct Dyn  2018; 36(14): 3636-50.
[http://dx.doi.org/10.1080/07391102.2017.1394221] [PMID:  29048995] 
[70] 
Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science  1999; 283(5407): 1544-8.
[http://dx.doi.org/10.1126/science.283.5407.1544] [PMID:  10066179] 
[71] 
Xie L, Lee SY, Andersen JN, et al. Cellular effects of small molecule PTP1B inhibitors on insulin signaling. Biochemistry  2003; 42(44): 12792-804.
[http://dx.doi.org/10.1021/bi035238p] [PMID:  14596593] 
[72] 
Liu GX, Tan JZ, Niu CY, et al. Molecular dynamics simulations of interaction between protein-tyrosine phosphatase 1B and a bidentate inhibitor. Acta Pharmacol Sin  2006; 27(1): 100-10.
[http://dx.doi.org/10.1111/j.1745-7254.2006.00251.x] [PMID:  16364216] 
[73] 
Malla P, Kumar R, Kumar M. Validation of formylchromane derivatives as protein tyrosine phosphatase 1B inhibitors by pharmacophore modeling, atom-based 3D-QSAR and docking studies. Chem Biol Drug Des  2013; 82(1): 71-80.
[http://dx.doi.org/10.1111/cbdd.12135] [PMID:  23506477] 
[74] 
Malla P, Kumar R, Mattewal SK, Mahapatra MK, Kumar M. A paradigm for development of novel PTP 1B inhibitors: Pharmacophore modelling, atom-based 3D-QSAR and docking studies. Med Chem Res  2013; 23: 927-38.
[http://dx.doi.org/10.1007/s00044-013-0690-5] 
[75] 
Chandra S, Pandey J, Tamrakar AK, Siddiqi MI. Multiple machine learning based descriptive and predictive workflow for the identification of potential PTP1B inhibitors. J Mol Graph Model  2017; 71: 242-56.
[http://dx.doi.org/10.1016/j.jmgm.2016.10.020] [PMID:  28006676] 
[76] 
Simon S, Sunil S, Renuka R, Abraham E. Review on sodium
	glucose co-transpopter-2 (SGLT2) inhibitors: a new class of antidiabetic
	drug IAJPS 2017; 4(10) 
[77] 
Nakka S, Guruprasad L. Structural insights into the active site of human sodium dependent glucose co-transporter 2: homology modelling, molecular docking, and 3D - QSAR studies. Aust J Chem  2012; 65(5): 1314-24.
[http://dx.doi.org/10.1071/CH12051] 
[78] 
Yuan JT, Yu SL, Gao SF, et al. Predicting the biological activities of triazole derivatives as SGLT2 inhibitors using multilayer perceptron neural network, support vector machine, and projection pursuit regression models. Chemom Intell Lab Syst  2016; 156: 166-73.
[http://dx.doi.org/10.1016/j.chemolab.2016.06.002] 
[79] 
Toulis KA, Nirantharakumar K, Pourzitaki C, Barnett AH, Tahrani AA. Glucokinase activators for type 2 diabetes: Challenges and future developments. Drugs  2020; 80(5): 467-75.
[http://dx.doi.org/10.1007/s40265-020-01278-z] [PMID:  32162273] 
[80] 
Johnson TO, Humphries PS. Glucokinase activators for the treatment of type 2 diabetes. Annu Rep Med Chem  2006; 41: 141-54.
[http://dx.doi.org/10.1016/S0065-7743(06)41008-3] 
[81] 
de Assis TM, Gajo GC, de Assis LC, et al. QSAR models guided by molecular dynamics applied to human glucokinase activators. Chem Biol Drug Des  2016; 87(3): 455-66.
[http://dx.doi.org/10.1111/cbdd.12683] [PMID:  26547388] 
[82] 
Saihi Y, Kraim K, Ferkous F, Djeghaba Z, Azzouzi A, Benouis S. Nonlinear QSAR study of xanthone and curcuminoid derivatives as α-glucosidase inhibitors. Bull Korean Chem Soc  2013; 34: 1643-50.
[http://dx.doi.org/10.5012/bkcs.2013.34.6.1643] 
[83] 
Bharathkumar H, Sundaram MS, Jagadish S, et al. Novel benzoxazine-based aglycones block glucose uptake in vivo by inhibiting glycosidases. PLoS One  2014; 9(7)e102759
[http://dx.doi.org/10.1371/journal.pone.0102759] [PMID:  25047583] 
[84] 
Asadollahi-Baboli M, Dehnavi S. Docking and QSAR analysis of tetracyclic oxindole derivatives as α-glucosidase inhibitors. Comput Biol Chem  2018; 76: 283-92.
[http://dx.doi.org/10.1016/j.compbiolchem.2018.07.019] [PMID:  30103106] 
[85] 
Li G, Huan Y, Yuan B, et al. Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents. Eur J Med Chem  2016; 124: 103-16.
[http://dx.doi.org/10.1016/j.ejmech.2016.08.023] [PMID:  27560285] 
[86] 
Li G, Meng B, Yuan B, et al. The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119. Eur J Med Chem  2020; 188112017
[http://dx.doi.org/10.1016/j.ejmech.2019.112017] [PMID:  31926470] 
Cite As
Current Pharmaceutical Design

Application of Machine Learning Methods for the Development of Antidiabetic Drugs

Abstract
